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3 patients were included recently and no data are available at this moment. Until now 15 patients (with a majority of
genotype non 2,3 and high viral load) completed a complete course of 48 weeks. Of those 15 patients, 6 patients had
positive PCR at week 24 and stopped treatment. One patient had negative PCR at week 24 but presented a breakthrough
afterwards. Another patient stopped treatment because of adverse events. So 7 out of the 15 patients completed 48 weeks
of treatment and had an End of Treatment response (ITT : 41%, PP : 50%). Follow-up of 24 weeks is now completed
in 5 of those patients and all of them showed a Sustained virological response (ITT : 33%, PP : 42%). Concerning
transaminases, it was interesting to see that ALT values divided by the ALT Upper Limit value (lab dependent) times
100, were lower for the F1 grade (66.5) compared to the F2 grade (81,0), but the difference was not statistically signif-
icant. Only two patients in the treatment group presented a very moderate flare up with ALT levels staying below two
times upper limit of normal. Concerning histology moderate fibrosis F2 was found in 12 patients (28%) at baseline. 7
of them were randomised in the treatment group. At this moment not enough results on histological evolution are avail-
able.
Conclusion : In this difficult to treat group of patients with chronic HCV and persistently normal transaminases com-
bination therapy with peginterferon alfa-2b plus ribavirin seems to be safe and beneficial regarding end of treatment and
sustained virological response. A positive but non significant correlation was found between ALT values and stage of
fibrosis. Final results have to be awaited and should be confirmed in a larger sample of patients.
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Introduction : Two-stage liver transplantation, i.e. a procedure rendering a patient anhepatic for a uncertain period of
time before registration for emergent liver transplantation (LT), has been seldom described in case of unstable fulmi-
nant liver failure, of massive hepatic trauma or liver graft primary non function (PNF). In this report the authors describe
their experience in early liver graft removal after LT.
Patients and methods : Four young female patients (mean age 36 years) underwent LT for various etiologies (PSC,
HBV-HCC, alcohol-paracetamol, idiopathic cirrhosis). All underwent early (day 0 to day 14) emergent total liver graft
removal for various reasons (uncontrollable preoperative hemorrhage, uncontrollable postoperative hemorrhage due to
PNF, graft necrosis due to vascular occlusion) and were registered for urgent reLT. All went back to the ICU in an anhep-
atic state and underwent maximal supportive therapy including CVVH and MARS support (1 case). Body temperature
was maintained between 34 and 37°C. 
Results : All patients survived until a cadaveric liver graft became available. In 3 cases they underwent reLT after a
mean anhepatic phase of 21 hours. Two survived without any sequel and are alive and well at follow-up. The fourth
patient experienced an anhepatic phase of 84 hours. After reLT, the patient fully recovered from the neurologic point of
vue and was extubated. She eventually died from multiple organ failure 14 days after reLT. 
Discussion : These cases illustrate that survival in anhepatic state is possible for at least 24 hrs. The potential full neu-
rologic recovery after 84 hours of anhepatic state (the longest ever reported to date) raises several questions on the
pathogenesis of intracranial hypertension in acute liver failure, reinforcing the “toxic liver” hypothesis in the etiology
of brain edema in this setting.





44,7 years > 850.000 : 21(49%)
< 850.000 : 11 (25,5%)
Not known :11(25,5%)
1 : 16 (37%)
2,3 : 5 (12%)
4 : 11 (25,5%)
Not known :11(25,5%)
F0 : 4 (9%)
F1 : 19 (44%)
F2 : 12 (28%)





45,6 years > 850.000 : 10 (50%)
< 850.000 : 4 (20%)
Not known : 6 (30%)
1 : 8 (40%)
2,3 : 2(10%)
4 : 7(35%)
Not known : 3(15%)
F0 : 0
F1 : 6 (30%)
F2 : 7 (35%)
Not comp : 7 (35%)
Control group
(n = 23)
14F/9 M 44 years > 850.000 : 11 (48%)
< 850.000 : 7 (30%)
Not known : 5 (22%)
1 : 8(35%)
2,3 : 3 (13%)
4 : 4 (17%)
Not known : 8 (35%)
F0 : 4 (17%)
F1 : 13(57%)
F2 : 5 (22%)
Not comp : 1 (4%)
